JOHNSON & JOHNSON Business Summary

Johnson & Johnson (JNJ) operates as a global healthcare powerhouse, generating revenue through the research-driven sale of proprietary pharmaceuticals and advanced medical technologies. Following the 2023 divestiture of its consumer health arm, Kenvue, the company is structured into two core segments: Innovative Medicine and MedTech. Innovative Medicine drives growth through high-margin treatments in oncology, immunology, and neuroscience, while MedTech focuses on interventional solutions, surgery, and cardiovascular devices, including the integrated Shockwave Medical and Abiomed portfolios. The company employs a transactional revenue model bolstered by licensing royalties and a $17 billion annual R&D commitment. J&J competes directly with Pfizer, Merck & Co., and AbbVie in pharmaceuticals, and Medtronic and Stryker in medical technology, maintaining a dominant market position as the world’s largest healthcare firm by leveraging its immense scale to navigate patent expirations and pricing reforms. Founded in 1886 by Robert, James, and Edward Mead Johnson, the company is currently led by Chairman and CEO Joaquin Duato, who has steered the firm’s transition into a high-growth, pure-play healthcare entity. The leadership team includes Executive Vice President and CFO Joseph J. Wolk, a key architect of the company’s capital allocation strategy, and Dr. John C. Reed, Executive Vice President of Innovative Medicine R&D, who previously held senior roles at Sanofi and Roche. The Board of Directors provides deep regulatory and operational expertise, featuring Lead Independent Director Anne Mulcahy (former Xerox CEO), Mark McClellan (former FDA Commissioner), and Marillyn Hewson (former Lockheed Martin CEO). Publicly traded as a Dow 30 component, J&J is primarily held by institutional giants Vanguard, BlackRock, and State Street, supporting a strategy focused on high-complexity surgical robotics and a pharmaceutical pipeline targeting double-digit growth by the end of the decade.